Dr. Michelangelo Certo earned his MSc in Pharmaceutical Chemistry and Technology with honors in 2010, followed by a PhD in Cellular Biochemistry and Pharmacology in 2013, both from the University of Calabria, Italy. He pursued postdoctoral research at the Centre of Preclinical and Translational Pharmacology, where he focused on elucidating the interactions between the immune system and the brain during ischemic injury, aiming to identify novel immunotherapeutic strategies for stroke.

In 2015, Dr. Certo was recognized as an expert in Pharmacology (BIO/14) by the Department Council at the School of Pharmacy, University of Calabria. The following year, he was awarded a prestigious Research Fellowship by the Italian Society of Pharmacology, which led him to join University College London, where he applied his expertise to the field of chronic pain.

Dr. Certo's research has consistently centered on the inflammatory mechanisms that govern immunity, with a strong emphasis on therapeutic innovation. His work spans cell trafficking, target identification, therapeutic exploitation, and the development of reparative and regenerative therapies. In 2017, he transitioned to Barts and The London School of Medicine and Dentistry at Queen Mary University of London, where his research delved into the metabolic regulation of immune cell functions and how specific metabolites, such as lactate and fatty acids, act as signaling molecules modulating immune-inflammatory responses.

In 2018, Dr. Certo joined the Institute of Inflammation and Ageing at the University of Birmingham as a Senior Research Fellow in Metabolism and Inflammation. His current research focuses on the intricate connections between metabolic and inflammatory pathways, investigating how these processes contribute to stroke (funded by the University of Birmingham), and chronic inflammatory diseases, including atherosclerosis (funded by the British Heart Foundation) and Sjögren's syndrome (funded by the Medical Research Council).